Skip to main content

RheumNow Podcast- Corona Increases RA Risk (3.13.20)

Mar 13, 2020 12:15 pm

Dr. Jack Cush reviews the news and journal articles from the past week on

  1. TNF inhibitors may slow, but do not stop, Xray progression in AS, Anti–IL-17A agents may maybe the same. Study by Inman et al shows that Tyk2 inhibition may prevent xray damage (animal model) by blocking IL-23 signaling and IL-22 production.
  2. CORRONA study of 24,528 #RA pts; 32% also has Sjogrens syndrome (overall SS prevalence in RA = 0.30 ). SS more likely with increasing RA duration, older, female, seropositive; higher DZ activity; more comorbidities and extra-articular manifestations
  3. Study of 179 RA pts, 21% with ILD, shows Anti-CarP Abs were strongly associated with ILD (OR 3.4). The role of homocitrullination in RA-ILD merits further investigation.
  4. Rheumatic dz pts from British Columbia; compared 185 DMARD exposed Pregnancies vs 6,064 PREG NOT exposed. HCQ, AZA, SSZ before/during PREG not assoc w/ SGA births. 1st trimester MTX incr odds for congenital anomalies (aOR 6.58; 1.15-37.75).
  5. UK population study shows that being over age 65 yrs increased the odds of receiving Seasonal influenza vaccination; but was without a reduction in hospitalizations or mortality among elderly persons. Call for new strategies
  6. EHR analysis of two health systems on finds among 3,577 # RA pts; 507 smoked and 29% quit over 4.7 yrs. More likely to quit were new Care pts (aOR 1.60), and rural community health system pts (1.66); Seropositives were less likely to quit (0.57)
  7. 1 year results of the ustekinumab in SLE trial encouraging. 1st 6 mos DBRPCT showed UST 62% vs PBO 33%. At wk 48 UST SRI4 responses maintained 63.3%; PBO crossovers caught up. 15% had seriour adverse events.
  8. Korean National Health claims study shows there was a significant increased risk of incident #RA 6-7 weeks following respiratory viral infections (parainfluenza, coronavirus, metapneumovirus), most evident in women and elderly.
  9. EMA Final Recommendations on VTE Risk with Tofacitinib


The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.